Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ocular Therapeutix, Inc. filings document the formal disclosure record for a Nasdaq-listed biopharmaceutical issuer developing and commercializing ophthalmic therapies. Form 8-K reports furnish operating and financial results, Regulation FD materials and clinical-trial disclosures tied to AXPAXLI in wet age-related macular degeneration, along with material-event reporting on governance matters, executive officer arrangements, material agreements and capital-structure disclosures.
Proxy materials cover shareholder voting matters, executive compensation and equity-award disclosures, including information presented under pay-versus-performance reporting. The filings also identify Ocular Therapeutix common stock, par value $0.0001 per share, as registered on The Nasdaq Global Market under the symbol OCUL.
Ocular Therapeutix, Inc.’s Chief Medical Officer, Nadia Waheed, reported an open-market sale of 14,828 shares of common stock at a weighted average price of $8.27 per share. The sale was made under a pre-established durable automatic sale instruction to cover tax withholding tied to restricted stock units vesting on June 1, 2026, and was not a discretionary trade. Following this transaction, she directly holds 300,079 shares of common stock.
OCUL filed a Form 144 notifying the planned sale of 14,828 common shares tied to restricted stock vesting under a registered plan. The shares are scheduled for 06/01/2026 and the filing appears on 06/03/2026 for NASDAQ trading.
The filing lists an aggregate dollar figure of $122,648.32 associated with the transaction and identifies the sale method as pursuant to a registered plan; additional proceeds treatment or holder details are not shown in the excerpt.
Ocular Therapeutix director and officer Pravin Dugel reported automatic tax‑related sales and internal share transfers. On May 26, 2026, 21,156 shares of common stock were sold at a weighted average price of $8.20 per share under a durable automatic sale instruction to cover tax withholding from restricted stock unit vesting. Following this sale, Dugel held 2,597,170 shares directly. On May 28, 2026, 394,696 shares previously held by his spouse were transferred for no consideration to the Pravin Dugel 2024 Irrevocable Trust, where he is trustee and lifetime beneficiary, leaving 694,811 shares in the trust and 0 in the spouse account while maintaining his beneficial ownership.
Ocular Therapeutix Chief Development Officer Peter Kaiser reported an open-market sale of 2,967 shares of common stock at a weighted average price of $8.20 per share on May 26, 2026, leaving him with 266,141 shares held directly.
According to the disclosure, these shares were sold under a durable automatic sale instruction adopted on April 9, 2024 to execute a sell-to-cover election for tax withholding related to restricted stock units vesting on May 22, 2026. The filing states that the sales do not represent a discretionary trade by Kaiser.
Ocular Therapeutix’s Chief Scientific Officer Jeffrey S. Heier reported an open-market sale of 3,018 shares of common stock at a weighted average price of $8.20 per share.
According to the footnotes, the sale was executed under a durable automatic sale instruction adopted on April 9, 2024 to effect a sell-to-cover election for tax withholding tied to restricted stock units vesting on May 22, 2026, and does not represent a discretionary trade. Following the transaction, Heier directly holds 320,350 shares of Ocular Therapeutix common stock.
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak reported an open-market sale of 1,858 shares of common stock on May 26, 2026 at a weighted average price of $8.20 per share. The transaction was executed under a durable automatic sale instruction to effect a sell-to-cover election for tax withholding tied to restricted stock units vesting on May 22, 2026, and was not a discretionary trade. Following this sale, Nayak directly holds 328,795 shares of Ocular Therapeutix common stock.
OCUL notice: Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell 1,858 shares of Common Stock relating to restricted stock vesting under a registered plan dated 05/22/2026. The filing lists a company reference date of 05/26/2026.
Company files a Form 144 notice to sell 2,967 shares of Common Stock. The filing states the securities are restricted stock vesting under a registered plan and lists an intended sale date of 05/22/2026. The securities are associated with trading on NASDAQ.
OCUL affiliate filed a Form 144 proposing the sale of 3,018 shares of Common Stock. The transaction is described as restricted stock vesting under a registered plan with a proposed sale date of 05/22/2026 and the Form 144 filing dated 05/26/2026.
The filing reports a Rule 144 notice for 21,156 shares of Common Stock associated with restricted stock vesting under a registered plan. The notice lists the transaction date as 05/22/2026 and identifies the filer as Morgan Stanley Smith Barney LLC.
This form records the planned sale under Rule 144; no proceeds, price, or purchaser details are included in the provided excerpt.